Are Ocular and Serum Half-Lives After Ranibizumab Intravitreal Injection Dependent on Dose?

Transl Vis Sci Technol. 2023 Apr 3;12(4):9. doi: 10.1167/tvst.12.4.9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiogenesis Inhibitors* / therapeutic use
  • Bevacizumab
  • Eye
  • Intravitreal Injections
  • Ranibizumab*

Substances

  • Ranibizumab
  • Angiogenesis Inhibitors
  • Bevacizumab